PAR HEALTH supplier risk profile Q1 2026: 76 shipments, Belgium-India sourcing footprint.
PAR HEALTH imported 76 shipments in Q1 2026 from 5 suppliers across 2 countries. Belgium accounted for 65.8% of shipments (50 total), while India represented 34.2% (26 shipments). The company's supply chain is concentrated among three primary sources: BOMI in Belgium (39 shipments), PAR Formulations Private in India (26 shipments), and PAR Formulations Private in Belgium (8 shipments). No HS classification data was available for categorization.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
PAR HEALTH registered zero matches on sanctions watchlists in Q1 2026. The company has zero suppliers with documented forced-labor exposure under UFLPA proximity screening. The importer's overall risk score is 83 (Grade A).
5 distinct tier-1 suppliers in Q1 2026
| BOMI | Belgium | 39 |
| PAR FORMULATIONS PRIVATE | India | 26 |
| PAR FORMULATIONS PRIVATE | Belgium | 8 |
| FAREVA MIRABEL | Belgium | 2 |
| WEST PHARMACEUTICAL SERVICES DEUTSC | Belgium | 1 |
Share of Q1 2026 inbound shipments by source country
4 tier-2 + 12 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.